📊 MDGL Key Takeaways
Is MDGL a Good Investment? Thesis Analysis
Despite exceptional 432% revenue growth, Madrigal Pharmaceuticals remains deeply unprofitable with -$288.3M net loss and negative operating margins of -31.3%, indicating the company is burning cash faster than revenue growth can support. The -$190M negative free cash flow coupled with $339.9M long-term debt raises serious sustainability concerns, suggesting the current business model is not yet generating value despite significant top-line expansion.
Why Buy MDGL? Key Strengths
- Exceptional revenue growth of 432% YoY demonstrates strong market demand and successful commercialization
- Strong liquidity position with $198.7M cash and 4.01x current ratio provides runway for operations
- Relatively moderate debt-to-equity ratio of 0.56x shows reasonable leverage levels
MDGL Investment Risks to Consider
- Severe profitability crisis: -$288.3M net loss and -$30.1% net margin indicate the company is unprofitable at scale
- Negative free cash flow of -$190M annually is unsustainable without capital raises or achieving profitability
- High cash burn rate relative to revenue suggests operational inefficiency and potential dilution risk for shareholders
- Negative interest coverage of -91.0x indicates inability to service debt from operations
Key Metrics to Watch
- Path to operating profitability and timeline to positive operating margins
- Operating cash flow trajectory and monthly cash burn rate sustainability
- Gross margin improvement as manufacturing scales and fixed costs are absorbed across higher revenue base
MDGL Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.01x current ratio provides a solid financial cushion.
MDGL Profitability Ratios
MDGL vs Healthcare Sector
How MADRIGAL PHARMACEUTICALS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MDGL Overvalued or Undervalued?
Based on fundamental analysis, MADRIGAL PHARMACEUTICALS, INC. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MDGL Balance Sheet & Liquidity
MDGL 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MADRIGAL PHARMACEUTICALS, INC.'s revenue has grown significantly by 432% over the 5-year period, indicating strong business expansion. The most recent EPS of $-19.99 indicates the company is currently unprofitable.
MDGL Growth Metrics (YoY)
MDGL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $62.2M | -$42.3M | $-4.92 |
| Q2 2025 | $14.6M | -$42.3M | $-1.90 |
| Q1 2025 | N/A | -$73.2M | $-3.32 |
| Q3 2024 | N/A | -$76.9M | $-4.92 |
| Q2 2024 | N/A | -$76.9M | $-4.69 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MDGL Capital Allocation
MDGL SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MADRIGAL PHARMACEUTICALS, INC. (CIK: 0001157601)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772842708.xml | View → |
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772840956.xml | View → |
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772840042.xml | View → |
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772838950.xml | View → |
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772838445.xml | View → |
❓ Frequently Asked Questions about MDGL
What is the AI rating for MDGL?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MDGL's key strengths?
Claude: Exceptional revenue growth of 432% YoY demonstrates strong market demand and successful commercialization. Strong liquidity position with $198.7M cash and 4.01x current ratio provides runway for operations.
What are the risks of investing in MDGL?
Claude: Severe profitability crisis: -$288.3M net loss and -$30.1% net margin indicate the company is unprofitable at scale. Negative free cash flow of -$190M annually is unsustainable without capital raises or achieving profitability.
What is MDGL's revenue and growth?
MADRIGAL PHARMACEUTICALS, INC. reported revenue of $958.4M.
Does MDGL pay dividends?
MADRIGAL PHARMACEUTICALS, INC. does not currently pay dividends.
Where can I find MDGL SEC filings?
Official SEC filings for MADRIGAL PHARMACEUTICALS, INC. (CIK: 0001157601) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MDGL's EPS?
MADRIGAL PHARMACEUTICALS, INC. has a diluted EPS of $-12.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MDGL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MADRIGAL PHARMACEUTICALS, INC. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MDGL stock overvalued or undervalued?
Valuation metrics for MDGL: ROE of -47.8% (sector avg: 15%), net margin of -30.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MDGL stock in 2026?
Our dual AI analysis gives MADRIGAL PHARMACEUTICALS, INC. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MDGL's free cash flow?
MADRIGAL PHARMACEUTICALS, INC.'s operating cash flow is $-189.6M, with capital expenditures of $467.0K. FCF margin is -19.8%.
How does MDGL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -30.1% (avg: 12%), ROE -47.8% (avg: 15%), current ratio 4.01 (avg: 2).